Cargando…
Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial
BACKGROUND: Irritable bowel syndrome (IBS) is a common functional bowel disorder. The global incidence of IBS is as high as 9% to 23%, accounting for about 50% of outpatients in gastroenterology, and the new case detection rate is 0.2% every year. IBS has become a global gastrointestinal functional...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837987/ https://www.ncbi.nlm.nih.gov/pubmed/33545956 http://dx.doi.org/10.1097/MD.0000000000023887 |
_version_ | 1783643070372249600 |
---|---|
author | Yang, Hongmei Liu, Xin Peng, Wei Chen, Rong Chen, Yang |
author_facet | Yang, Hongmei Liu, Xin Peng, Wei Chen, Rong Chen, Yang |
author_sort | Yang, Hongmei |
collection | PubMed |
description | BACKGROUND: Irritable bowel syndrome (IBS) is a common functional bowel disorder. The global incidence of IBS is as high as 9% to 23%, accounting for about 50% of outpatients in gastroenterology, and the new case detection rate is 0.2% every year. IBS has become a global gastrointestinal functional disease. Although IBS is not a life-threatening disease, it seriously affects the quality of life of patients, causing huge economic and mental burden to individuals, society and families. Lipi Guben decoction (LPGBD) is an important auxiliary treatment for IBS, but lack of robust Evidence-based medicine evidence proving its efficacy. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of LPGBD in the treatment of IBS. METHODS: In this randomized controlled trial, a total of 100 eligible patients will be allocated to the blank control group or LPGBD group in a ratio of 1:1. The treatment period was 12 weeks. The primary outcome measure will be the total clinical effective rate. The Secondary outcomes will include IBS clinical symptom scores, IBS-Severity Scoring System, IBS-Quality of life, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Bristol Stool Form Scale. The safety outcome will include Echocardiogram, blood examination (including blood routine test, liver function test, and renal function test), urine routine test and stool routine test. The evaluation indicators and all safety results will be performed at baseline, week 4, week 8 and week 12. RESULTS: This study will be helpful to evaluate the efficacy and safety of LPGBD in the treatment of IBS. CONCLUSION: LPGBD may improve the clinical efficacy of patients with IBS, which has important value in practical application TRIAL REGISTRATION: Chictr20000039617, registration time: November 3, 2020 |
format | Online Article Text |
id | pubmed-7837987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-78379872021-01-28 Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial Yang, Hongmei Liu, Xin Peng, Wei Chen, Rong Chen, Yang Medicine (Baltimore) 3800 BACKGROUND: Irritable bowel syndrome (IBS) is a common functional bowel disorder. The global incidence of IBS is as high as 9% to 23%, accounting for about 50% of outpatients in gastroenterology, and the new case detection rate is 0.2% every year. IBS has become a global gastrointestinal functional disease. Although IBS is not a life-threatening disease, it seriously affects the quality of life of patients, causing huge economic and mental burden to individuals, society and families. Lipi Guben decoction (LPGBD) is an important auxiliary treatment for IBS, but lack of robust Evidence-based medicine evidence proving its efficacy. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of LPGBD in the treatment of IBS. METHODS: In this randomized controlled trial, a total of 100 eligible patients will be allocated to the blank control group or LPGBD group in a ratio of 1:1. The treatment period was 12 weeks. The primary outcome measure will be the total clinical effective rate. The Secondary outcomes will include IBS clinical symptom scores, IBS-Severity Scoring System, IBS-Quality of life, Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Bristol Stool Form Scale. The safety outcome will include Echocardiogram, blood examination (including blood routine test, liver function test, and renal function test), urine routine test and stool routine test. The evaluation indicators and all safety results will be performed at baseline, week 4, week 8 and week 12. RESULTS: This study will be helpful to evaluate the efficacy and safety of LPGBD in the treatment of IBS. CONCLUSION: LPGBD may improve the clinical efficacy of patients with IBS, which has important value in practical application TRIAL REGISTRATION: Chictr20000039617, registration time: November 3, 2020 Lippincott Williams & Wilkins 2021-01-22 /pmc/articles/PMC7837987/ /pubmed/33545956 http://dx.doi.org/10.1097/MD.0000000000023887 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 3800 Yang, Hongmei Liu, Xin Peng, Wei Chen, Rong Chen, Yang Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title | Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title_full | Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title_fullStr | Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title_full_unstemmed | Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title_short | Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial |
title_sort | lipi guben decoction in treating diarrheal irritable bowel syndrome: a study protocol for a randomized controlled trial |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837987/ https://www.ncbi.nlm.nih.gov/pubmed/33545956 http://dx.doi.org/10.1097/MD.0000000000023887 |
work_keys_str_mv | AT yanghongmei lipigubendecoctionintreatingdiarrhealirritablebowelsyndromeastudyprotocolforarandomizedcontrolledtrial AT liuxin lipigubendecoctionintreatingdiarrhealirritablebowelsyndromeastudyprotocolforarandomizedcontrolledtrial AT pengwei lipigubendecoctionintreatingdiarrhealirritablebowelsyndromeastudyprotocolforarandomizedcontrolledtrial AT chenrong lipigubendecoctionintreatingdiarrhealirritablebowelsyndromeastudyprotocolforarandomizedcontrolledtrial AT chenyang lipigubendecoctionintreatingdiarrhealirritablebowelsyndromeastudyprotocolforarandomizedcontrolledtrial |